Diabetic kidney disease has a high global disease burden and substantially increases the
risk of kidney failure and cardiovascular events. Despite treatment, there is substantial …

The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline
for Diabetes Management in Chronic Kidney Disease (CKD) represents a focused update of …

Background The effects of empagliflozin in patients with chronic kidney disease who are at
risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed …

Background Large trials have shown that sodium glucose co-transporter-2 (SGLT2)
inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with …

Background Sparsentan is a novel, non-immunosuppressive, single-molecule, dual
endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial …

SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …

This article is published as part of a supplement sponsored by Kidney Disease: Improving
Global Outcomes (KDIGO). The opinions or views expressed in this supplement are those of …

Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) were originally developed as
antidiabetic agents, with cardiovascular (CV) outcome trials demonstrating improved CV …

Although patients with heart failure with preserved ejection fraction (HFpEF)(left ventricular
ejection fraction≥ 50%) comprise nearly half of those with chronic heart failure, evidence …

This guideline synthesizes clinical trial data supporting the role of glucagon-like peptide-1
receptor agonists and sodium-glucose co-transporter 2 inhibitors (SGLT2i) for treatment of …